Nov 28, 2016 11:30 am UTC| Business
FDA Grants Tazemetostat Fast Track Designation for DLBCL with EZH2 Activating Mutations Company Focuses Phase 2 Solid Tumor Study on INI1-Negative Tumors and Expands Epithelioid Sarcoma Cohort CAMBRIDGE, Mass., Nov. ...
Nov 28, 2016 11:15 am UTC| Business
DENVER, Nov. 28, 2016 -- Centennial Resource Development, Inc. together with its affiliates (“CDEV”, “Centennial” or the “Company”) (NASDAQ:CDEV) (NASDAQ:CDEVW), today announced that it has agreed to acquire 100% of the...
Nov 28, 2016 11:11 am UTC| Business
Martinsried / Munich, Germany, Nov. 28, 2016 -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that its licensee Janssen Research Development, LLC (Janssen) through one of its...
YY Inc. Announces 2016 Annual General Meeting Results
Nov 28, 2016 11:00 am UTC| Business
GUANGZHOU, China, Nov. 28, 2016 -- YY Inc. (NASDAQ:YY) (“YY” or the “Company”), a live streaming platform, today announced the results of its 2016 annual general meeting of shareholders held in Hong Kong on November 28,...
Nov 28, 2016 11:00 am UTC| Business
ANAHEIM, CA, Nov. 28, 2016 -- BioCorRx Inc. (OTC PINK: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, announces several operational developments...
Nov 28, 2016 11:00 am UTC| Business
ROYAL-1 is a Phase 2b Study to Determine Safety and Tolerability of Gemcabene in Hypercholesterolemia Not Adequately Controlled on High-Intensity or Moderate-Intensity Stable Statin Therapy Topline Data Readout...
AngioDynamics to Participate in Upcoming Investor Conferences
Nov 28, 2016 11:00 am UTC| Business
ALBANY, N.Y., Nov. 28, 2016 -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today...
U.S. Appeals Court Allows Trump Administration to Enforce Medicaid Funding Ban on Planned Parenthood